Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00470093 · ClinicalTrials.gov registry record · Early Phase 1
Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma
A Early Phase 1 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
NCT00470093 is a Early Phase 1 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 3 participants.
The verdict
NCT00470093, a Early Phase 1 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-6 may stimulate the white blood cells to kill cancer cells. Giving interferon alfa together with interleukin-6 may kill more cancer cells. PURPOSE: This clinical trial is studying the side effects and how well giving interferon alfa together with interleukin-6 works in treating patients with recurrent multiple myeloma.
Interventions
- BIOLOGICAL recombinant interferon-α
- BIOLOGICAL recombinant interleukin-6
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2007-10 |
| Est. Completion | 2010-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00470093
The ClinicalTrials.gov registry entry for NCT00470093 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which recombinant interferon-α is the first listed.
NCT00470093 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00470093 about?
NCT00470093 is a clinical study titled "Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma". RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-6 may stimulate the white blood cells to kill cancer cells. Giving interferon alfa together with interleukin-6 may kill more cancer cells. PURPOSE: This clinical trial is studying the side effects and how well giv...
What is the current status of trial NCT00470093?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2007-10. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00470093?
The interventions under investigation include: recombinant interferon-α (BIOLOGICAL), recombinant interleukin-6 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00470093?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.